David Halpin United Kingdom

Professor Halpin is Professor of Respiratory Medicine at the University of Exeter and at the Observational and Pragmatic Research Institute, Singapore. He studied at Oxford University (first class honours) & St Thomas Hospital Medical School, and undertook a D.Phil. at Oxford University, between his pre-clinical and clinical training. He trained in respiratory medicine at the Brompton Hospital in London. He is a member of the GOLD Board of Directors and Science Committee, and previously led the development of the NICE COPD Guideline. He sits on the Global Alliance against Chronic Respiratory Diseases (GARD) Steering Committee and on the Forum of International Respiratory Societies (FIRS) Executive Committee. He has published extensively and frequently lectures on COPD at meetings around the world. He led the recent work at the UN and WHA to ensure that COPD and asthma were specifically included in the UN declaration on NCDs.
Job Title
Member of GOLD Board of Directors & Science Committee
Faculty / Department / Division
University of Exeter Medical School
Institution / Organisation
Global Initiative for Chronic Obstructive Lung Disease – GOLD

20 November 2026, Friday

Time Session
09:30
11:00
  • Ahmad Izuanuddin Ismail Chairperson Malaysia
  • David Halpin Speaker United Kingdom
  • Antonio Anzueto Speaker United States
  • Wisia Wedzicha Speaker United Kingdom
    This presentation will review aspects of COPD exacerbation management in the GOLD 2027 report.
  • Pang Yong Kek Speaker Malaysia
    Title: Leveraging Digital Tools in COPD Management for 2027 & Beyond Routine outpatient management of COPD faces a double deficit: up to 70% of patients make critical inhaler errors, with real-world adherence below 50%, whilst fewer than 3% complete centre-based pulmonary rehabilitation (PR). Digital healthcare addresses this through two synergistic pillars: connected smart inhalers—which enhance adherence by 22%–35% and reduce exacerbations by 17%–30% via objective flow and technique tracking—and digital therapeutics like myCOPD and Kaia COPD, which improve exercise capacity (+57.68 m 6MWD) with outcomes non-inferior to in-person PR. Remote Therapeutic Monitoring (RTM) billing frameworks establish clinical and financial viability by reimbursing multidisciplinary management of non-physiological data, medication adherence, and patient-reported outcomes. Looking toward 2027, multi-modal data fusion—integrating wearable vitals, acoustic cough biomarkers, and smart inhaler actuations—enables machine learning algorithms to forecast acute exacerbations up to 7 days ahead with 92% accuracy, aligning with recent GOLD strategy updates on early phenotypes (Pre-COPD/PRISm) and AI integration. Crucially, digital tools fail in isolation: patient engagement drops to 20% without supervision but exceeds 85% within a structured "clinician-in-the-loop" model, proving human clinical oversight remains essential for successful digital transformation.
  • Ahmad Izuanuddin Ismail Chairperson Malaysia
    Pang Yong Kek Chairperson Malaysia
Ballroom 1, Lower Ground Floor